A study of NTQ5082 for PNH patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with PNH and over 10% of your PNH cells are affected.
- You have never taken a complement inhibitor (like eculizumab) for PNH.
- Your hemoglobin (a red blood cell measure) is low (below 100 g/L) or you needed a blood transfusion for PNH-related anemia recently.
- Your LDH level (a marker of red blood cell breakdown) is more than 1.5 times the normal upper limit.
- You do not have certain other medical conditions or recent treatments that would exclude you, such as severe bone marrow failure, recent infections, or use of certain medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial is testing a new pill (FXS6837) compared to the standard IV medicine eculizumab for people with PNH. The study lasts 24 weeks and aims to see if the new pill works better or as well and has fewer side effects.
This trial tests the long-term safety and effectiveness of NTQ5082 for people who have already taken part in a previous NTQ5082 study and benefited from it, or who were in the control group and received eculizumab. It aims to see if continued treatment is safe and helpful over a longer period.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.